ARVN - Arvinas: Tremendous Value Increase With Pfizer Mega-Deal High Potential
- ARVN is a pioneering protein degrader biopharma with strong early data.
- Recently, Pfizer inked a $2bn deal with the company for just one of its assets.
- The stock looks very promising despite its 52-week highs.
For further details see:
Arvinas: Tremendous Value Increase With Pfizer Mega-Deal, High Potential